SCHEMBL7207826

SCHEMBL7207826

CCOC(=O)c1n[c]ns1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
MAPT P10636 4/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
GAA P10253 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
CYP1A2 P05177 3/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 3/20 0.37
PDE4D Q08499 1/20 0.37
POLB P06746 2/20 0.36
ESR1 P03372 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NR4A1 P22736 1/20 0.36
FHIT P49789 1/20 0.36
CYP2C19 P33261 1/20 0.36
CA12 O43570 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL129628 0.69 MAPT (0.41) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL22578954 0.68 CYP1A2 (0.43) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL23291972 0.67 ALDH1A1 (0.47) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL2783298 0.67 HSD17B10 (0.42) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL970936 0.67 TSHR (0.41) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL9454202 0.66 RAB9A (0.66) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL128889 0.66 CA12 (0.42) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL18039508 0.66 CYP1A2 (0.41) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL25219857 0.66 CYP1A2 (0.41) ALDH1A1MAPTKMT2AMEN1NPC1
SCHEMBL4315953 0.65 ALDH1A1 (0.46) ALDH1A1MAPTKMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1286988-A2 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES Basilea Pharmaceutica AG (CH) 2003-03-05 EP claimed
US-20010047017-A1 Azole derivatives HOFFMANN-LA ROCHE, INC. 2001-11-29 US claimed
US-6319933-B1 1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives; fungicides BASILEA PHARMACEUTICA AG (CH) 2001-11-20 US claimed
WO-2001079196-A2 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES BASILEA PHARMACEUTICA AG (CH) 2001-10-25 WO claimed
EP-1286988-A2 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES Basilea Pharmaceutica AG (CH) 2003-03-05 EP disclosed
US-20010047017-A1 Azole derivatives HOFFMANN-LA ROCHE, INC. 2001-11-29 US disclosed
US-6319933-B1 1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives; fungicides BASILEA PHARMACEUTICA AG (CH) 2001-11-20 US disclosed
WO-2001079196-A2 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES BASILEA PHARMACEUTICA AG (CH) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047017-A1 Azole derivatives ERG28, CYP51A1, CYP3A5 ALDH1A1 757/4885MAPT 2247/4885KMT2A 2857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.